Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.

Torgersen J, Newcomb CW, Carbonari DM, et al. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol [Internet]. 2021;75(6):1312-1322. https://doi.org/10.1016/j.jhep.2021.07.021

Publication Type:

Journal Article

Authors:

Torgersen, J; Newcomb, CW; Carbonari, DM; et, al

Source:

J Hepatol, Volume 75, Issue 6, p.1312-1322 (2021)

URL:

https://doi.org/10.1016/j.jhep.2021.07.021

Keywords:

acute liver injury, Direct-acting antivirals, Hepatitis C, protease inhibitor

Cited On:

Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy

External Third-party Web Link:

https://pubmed.ncbi.nlm.nih.gov/34333102/

Export Citation:

RIS Format

Top